Met Life Investment Management, LLC Bluebird Bio, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

36 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$0.85 - $1.26 $9,955 - $14,757
11,712 Added 11.66%
112,154 $109,000
Q1 2024

May 14, 2024
BUY
$0.91 - $1.75 $91,402 - $175,773
100,442 New
100,442 $128,000
Q2 2023

Apr 29, 2024
BUY
$2.79 - $5.03 $152,130 - $274,270
54,527 New
54,527 $179,000
Q1 2023

May 09, 2024
BUY
$3.14 - $8.22 $171,214 - $448,211
54,527 New
54,527 $173 Million
Q1 2023

May 15, 2023
BUY
$3.14 - $8.22 $34,251 - $89,663
10,908 Added 25.01%
54,527 $173,000
Q4 2022

May 10, 2024
BUY
$5.77 - $8.49 $32,352 - $47,603
5,607 Added 14.75%
43,619 $301,000
Q4 2022

Jun 14, 2023
SELL
$5.77 - $8.49 $62,939 - $92,608
-10,908 Reduced 20.0%
43,619 $301,000
Q4 2022

Mar 22, 2023
BUY
$5.77 - $8.49 $32,352 - $47,603
5,607 Added 14.75%
43,619 $301,000
Q4 2022

Feb 15, 2023
BUY
$5.77 - $8.49 $32,352 - $47,603
5,607 Added 14.75%
43,619 $301,000
Q3 2022

Jun 14, 2023
SELL
$3.75 - $7.39 $61,931 - $122,045
-16,515 Reduced 30.29%
38,012 $240,000
Q2 2022

May 10, 2024
BUY
$2.94 - $5.23 $67,411 - $119,918
22,929 Added 152.02%
38,012 $157,000
Q2 2022

Jun 20, 2023
SELL
$2.94 - $5.23 $48,554 - $86,373
-16,515 Reduced 30.29%
38,012 $157,000
Q2 2022

Mar 22, 2023
BUY
$2.94 - $5.23 $67,411 - $119,918
22,929 Added 152.02%
38,012 $157,000
Q2 2022

Aug 11, 2022
BUY
$2.94 - $5.23 $67,411 - $119,918
22,929 Added 152.02%
38,012 $157,000
Q1 2022

May 10, 2024
BUY
$4.07 - $10.6 $61,387 - $159,879
15,083 New
15,083 $73,000
Q1 2022

Jun 20, 2023
SELL
$4.07 - $10.6 $160,537 - $418,106
-39,444 Reduced 72.34%
15,083 $73,000
Q1 2022

Mar 22, 2023
SELL
$4.07 - $10.6 $38,310 - $99,777
-9,413 Reduced 38.43%
15,083 $73,000
Q1 2022

May 12, 2022
SELL
$4.07 - $10.6 $38,310 - $99,777
-9,413 Reduced 38.43%
15,083 $73,000
Q4 2021

Jun 21, 2023
SELL
$8.96 - $16.31 $269,077 - $489,805
-30,031 Reduced 55.08%
24,496 $244,000
Q3 2021

Jun 21, 2023
SELL
$11.24 - $21.0 $337,548 - $630,651
-30,031 Reduced 55.08%
24,496 $303,000
Q2 2021

May 17, 2024
SELL
$18.04 - $22.09 $1.37 Million - $1.68 Million
-75,946 Reduced 75.61%
24,496 $507,000
Q2 2021

Jun 21, 2023
SELL
$18.04 - $22.09 $541,759 - $663,384
-30,031 Reduced 55.08%
24,496 $507,000
Q2 2021

Mar 22, 2023
BUY
$18.04 - $22.09 $428,576 - $524,792
23,757 Added 3214.75%
24,496 $507,000
Q2 2021

Aug 16, 2021
BUY
$18.04 - $22.09 $428,576 - $524,792
23,757 Added 3214.75%
24,496 $783,000
Q1 2021

Mar 22, 2023
BUY
$16.59 - $33.89 $11,032 - $22,536
665 Added 898.65%
739 $14,000
Q1 2021

May 14, 2021
BUY
$16.59 - $33.89 $12,260 - $25,044
739 New
739 $22,000
Q2 2019

Aug 14, 2019
SELL
$75.84 - $105.21 $5,612 - $7,785
-74 Closed
0 $0
Q1 2019

Jul 13, 2023
SELL
$64.44 - $104.11 $3.51 Million - $5.67 Million
-54,453 Reduced 99.86%
74 $7,000
Q4 2018

Jul 13, 2023
SELL
$59.1 - $93.26 $3.22 Million - $5.08 Million
-54,453 Reduced 99.86%
74 $4,000
Q4 2018

Mar 22, 2023
SELL
$59.1 - $93.26 $59 - $93
-1 Reduced 1.33%
74 $4,000
Q4 2018

Feb 14, 2019
SELL
$59.1 - $93.26 $59 - $93
-1 Reduced 1.33%
74 $7,000
Q3 2018

Jul 13, 2023
SELL
$88.86 - $117.49 $4.84 Million - $6.4 Million
-54,452 Reduced 99.86%
75 $7,000
Q3 2018

Mar 22, 2023
SELL
$88.86 - $117.49 $3.87 Million - $5.12 Million
-43,544 Reduced 99.83%
75 $7,000
Q3 2018

Nov 14, 2018
BUY
$88.86 - $117.49 $6,664 - $8,811
75 New
75 $11,000
Q1 2018

May 15, 2018
SELL
$105.8 - $150.94 $2.34 Million - $3.34 Million
-22,095 Closed
0 $0
Q4 2017

Feb 15, 2018
BUY
$81.25 - $130.7 $1.8 Million - $2.89 Million
22,095
22,095 $3.94 Million

Others Institutions Holding BLUE

# of Institutions
151
Shares Held
63.4M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $27M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email